Acute general Parkinson's disease monkey model and medicament screening method thereof

A Parkinson's disease, systemic technology, applied in the field of acute systemic monkey Parkinson's disease model and its drug screening, can solve the problems of poor stability of animal models

Active Publication Date: 2012-03-21
WEST CHINA HOSPITAL SICHUAN UNIV +2
View PDF6 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the dose was reduced, the pr

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Acute general Parkinson's disease monkey model and medicament screening method thereof
  • Acute general Parkinson's disease monkey model and medicament screening method thereof
  • Acute general Parkinson's disease monkey model and medicament screening method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Embodiment 1 Preparation of acute systemic monkey Parkinson's disease model of the present invention

[0027] 1. Purpose of the experiment

[0028] Establish a systemic MPTP monkey Parkinson's disease model with typical symptoms and conduct a comprehensive evaluation of the model to make it suitable for various researches such as new drug evaluation.

[0029] 2. Experimental method

[0030] 2.1 Experimental animals selected:

[0031] Referring to the inclusion criteria of experimental monkeys (see below), 3 healthy adult macaques were purchased from Chengdu Ping An Experimental Animal Breeding Center. Age 5-7 years, weight 5.0-6.1Kg, two males and one female, represented by M1, M2 and F1 respectively. After passing the inspection and quarantine, they are placed in the Large Animal Breeding Center of the National (Chengdu) Traditional Chinese Medicine Safety Assessment Center (GLP) for breeding.

[0032] Inclusion criteria for experimental monkeys:

[0033] ①, age 4...

Embodiment 2

[0109] Example 2 Validate the acute systemic monkey Parkinson's disease model with drugs for the treatment of acute Parkinson's disease and initially establish a related drug screening platform

[0110] A, get the acute systemic monkey Parkinson's disease model that embodiment 1 method establishes;

[0111] B, using currently recognized medicines for the treatment of acute Parkinson's disease (Madopar, Sining) administered to the acute systemic monkey Parkinson's disease model animals of the present invention;

[0112] c, observe the influence situation of candidate drug on the quantitative index of acute Parkinson's disease, and score (with the animal behavior score table of embodiment 1 Table 1), evaluate the medicine of potential treatment acute Parkinson's disease, also verified the present invention simultaneously Feasibility of using acute systemic monkey Parkinson's disease model animals for drug screening.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a preparation method for an acute general Parkinson's disease monkey model. The preparation method comprises the following step of: continuously applying 0.36 mg/kg of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) to a monkey for five times once every two days in an intravenous injection way. The invention provides a method for screening a medicament for treating the acute Parkinson's disease. By performing continuous peripheral vein injection of MPTP, an acute general Parkinson's disease monkey model with symptoms similar to those of an advanced-stage Parkinson's disease patient can be established. The model has stable symptoms within 1-4 months after establishment, and recovers rapidly later.

Description

technical field [0001] The invention relates to an acute systemic monkey Parkinson's disease model and a drug screening method thereof. Background technique [0002] There are many experimental animal models of Parkinson's disease (PD), including surgical injury of mice and rats or models of damage caused by stereotaxic injection of 6-hydroxydopa. The most valuable model animals should be species that have similar structure, function and complexity to the human nervous system, especially the basal ganglia of the midbrain. The primate PD animal model can reflect the basic characteristics of PD symptoms, and is currently the animal model closest to human PD, which provides a good foundation and platform for the basic research of PD. [0003] MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) causes damage to dopaminergic neurons in the substantia nigra-striatum region of the central nervous system. Although the hemimonkey Parkinson's disease model is simple to model, low in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/4418A61P25/16A61K49/00
Inventor 李鹏王伟王莉李宏霞刘文科徐策
Owner WEST CHINA HOSPITAL SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap